Mike,
Speaking about Glaxo's GG167 + QDEL's flu test, don't forget about QDEL's SAFEPLAN, their new method of birth control, which I think we'll be hearing about in the next year or so. QDEL doesn't talk about it much, but it is currently undergoing clinical trials. It is a better and cheaper and easier test than Unilever's Unipath test, which was featured in the Wall Street Journal a few months ago. The Principal Equity report failed to mention this test entirely in its report. Mike, I know you saw the blurb in BUSINESS WEEK about 4 years ago when QDEL initially filed Safeplan w/ the FDA. QDEL's then president, Scott Glenn, was quoted as saying this test could be worth $0.30 a share per year, as I recall. Unfortunately, the FDA ruled that the test was so revolutionary, it was denying QDEL's application for approval pending the results of clinical testing. Although I don't place much credence in Mr.Glenn's earnings projections. the test is potentially quite lucrative I believe and has not yet been factored in to anyone's earnings projections. This is just a long-winded way of telling both you and Steve that you made good investments in QDELW. I am considering placing a buy order for a substantial number of warrants at $1.50 and hoping the order executes before 3rd quarter results are released in late January,1997. I don't think the warrants will ever see $1.50 again after that.
BOB |
